Isatuximab After Allogeneic Stem Cell Transplant
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Sanofi
- Tags
- Monoclonal Antibody, CD38, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1937
- NCT Identifier
- NCT05873205
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.